In contrast to Caucasian populations, which are generally treated with CFTR modulators (82%, according to Annual Data Report 2022 of Cystic Fibrosis Foundation Patient Registry), the current treatments for Chinese patients mainly include airway clearance, long-term oral macrolides, pancreatic enzyme replacement, and antibiotic therapy during PEx [2]. This evidence concerns the gene CFTR and cystic fibrosis.